In a comparison of 18 countries, the United States ranked at the bottom for number of deaths that could have been prevented by timely and effective health care. Not only were U.S. rates among the worst, the rate of improvement from 1997-98 to 2002-03 was the smallest.

Congressional Budget Office (CBO) director Peter Orszag today continued his assault on the elephant in health policy’s living room, the 2.1 percent “excess cost growth” by which the nation’s total health spending growth has exceeded the growth in gross domestic product (GDP) since 1975. At a reporters’ briefing sponsored by Health Affairs, Orszag unveiled a […]

Editor’s Note: Why have so few provider groups undertaken the self-analysis that the Virginia Mason Medical Center (VMMC) entered into through its use of the famed Toyota Production System, even before Aetna and large employers began to push VMMC to cut costs? This is just one question posed by James C. Robinson, Berkeley economist and […]

This past month the most-read posts on the Health Affairs Blog focused particularly on the quest for value and quality via evidence-based medicine (EBM), comparative effectiveness lessons from the UK, and new research on quality and P4P. Other highly read posts covered the continuing presidential campaign and state health reform debates; immigration policy; and a […]

In an interview published online at Health Affairs [2-week free access], David Eddy, founder and medical director of Archimedes Inc. in Aspen, Colorado, discusses evidence-based medicine (EBM) with Sean Tunis, founder and director of the Center for Medical Technology Policy in San Francisco. Archimedes was founded to improve the quality and efficiency of health care […]

What happens when a government agency in charge of assessing the effectiveness of medical interventions crunches numbers and tells pharmaceutical companies their drugs are just too expensive? Sometimes, the government gets a better deal.
Twice last week, the much-feared National Institute for Health and Clinical Excellence (NICE) in England and Wales was a factor in drug […]